SCHEMBL264424

SCHEMBL264424

Cn1nccc1C(=O)Nc1ccc(-c2cc(F)ccc2OC(F)(F)F)c(N)n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 11/20 0.81
SCN5A Q14524 2/20 0.57
SCN9A Q15858 2/20 0.57
SCN1A P35498 1/20 0.57
SCN2A Q99250 1/20 0.54
SCN3A Q9NY46 1/20 0.54
MAP4K1 Q92918 1/20 0.39
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 1/20 0.39
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CSNK1D P48730 1/20 0.37
CSNK1E P49674 1/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ABL1 P00519 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14237517 0.92 SCN10A (0.79) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL263763 0.90 SCN10A (0.80) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL262570 0.90 SCN10A (1.00) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL262795 0.89 SCN10A (0.75) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL263007 0.88 SCN10A (0.67) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL262209 0.87 SCN10A (0.70) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL14237518 0.87 SCN10A (0.70) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL262687 0.87 SCN10A (0.72) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL3630599 0.86 SCN10A (0.64) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL14237287 0.86 SCN10A (0.71) SCN10ASCN5ASCN9ASCN1ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885SCN5A 157/4885SCN9A 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.